Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Recently published evidence has shown an improvement in locoregional control and a
survival advantage in the treatment of squamous cell carcinomas of the head and neck …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Abstract Background: Cetuximab (Erbitux) is the only new medical therapy for locally and
regionally advanced SCCHN to be licensed in industrialized countries in the past 15 years …

Cetuximab is an epidermal growth factor receptor inhibitor which has been recently focused
on the therapy of squamous cell carcinoma of the head and neck based on the nearly …

This is a comment on" Phase II multicenter study of the epidermal growth factor receptor
antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the …

Introduction The purpose of this study was to evaluate the clinical efficacy in our daily
practice, outside clinical trials, of cetuximab plus radiotherapy in a majority of treatment …

Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …